ORLANDO, FL--(Marketwire - April 4, 2012) - Quture International, Inc. (
The new peer review application in QualOptima will continue to advance peer review from anecdotal, unstructured and subjective to electronic, structured, and evidenced-based explicit analytics. The product will be introduced into a market for the peer review application, next to be enhanced with proctoring to complete the application, with a market potential estimated in excess of $500,000,000 in the United States alone.
"The prospects for Quture to change the peer review processes to enhance clinical performance and achieve optimal clinical outcomes was one of my primary motivations to join the Company," said Richard Fantozzi, M.D., CEO and Co-Chairman of Quture. "During my term with the medical board in California, we dealt frequently with peer review issues and had the opportunity to see the development of the Lumetra Report. When the results of that study were published, they confirmed my concern that peer review is an essential process, but is often poorly performed and under reported. We believe that there are other health communities that see the essential value of using the performance enhancement tool."
"Quture is poised to commercially market a truly revolutionary product to enhance performance measurement and to achieve what is possible to improve both healthcare delivery and payment systems internationally," he added.
The QualOptima System peer review application is the first commercial product release of Quture, soon to be enhanced with electronic proctoring and performance measurement following the Demonstration Projects at the University of Miami, Miller School of Medicine, Jackson Memorial Hospital, under the leadership of Keith Candiotti, M.D., and at Niagara Falls Memorial Medical Center, under the leadership of Judith Daugherty, R.N., Ph.D.
"My colleagues and I have worked for over 35 years and I have invested over $3 million to accomplish this new peer review application," said Landon Feazell, Chairman & CEO of Quture International, Inc. "It is truly remarkable that years of development of intellectual property and clinical content are now converging on a remarkable technology platform to derive clinical knowledge solutions. We can now replace outdated manual review yielding only anecdotal subjective data with limited impact on health care processes. Dr. Janice Ophoven, Chief Medical Officer of Quture and her team have worked with us throughout the years to develop these assets to transition to evidence-based, structured implicit review. I am proud and excited to finally begin to announce our accomplishments with this new technology and science of healthcare quality and patient safety."
QUTURE INTERNATIONAL, INC.
Quture International, Inc. is an emerging growth company positioned to become the leading clinical knowledge company in the world. The core competence of Quture is clinical performance enhancement to achieve optimal patient outcomes. Quture's brand is centered on the value proposition of trust, transparency and independence. As the free enterprise solution to improving health and health care while reducing costs, Quture is comprised of a subsidiary for the operations of its software technology solutions, plans for a "beyond data" consulting and knowledge applications company, as well as plans for a personalized, proactive, and predictive medicine company with a virtual community of members. These subsidiaries will all be affiliated with the Qx Medical Exchange, which the Company intends to become the largest medical and health exchange in the world. Quture International is a Nevada corporation currently trading under the symbol TCLN.
Quture, Inc. is the operations subsidiary of Quture International, Inc., positioned to become the international standard in healthcare performance, outcomes and analytics. Quture's transformational product QualOptima operates on the InterSystems technology platform, the leading software platform globally for health care. QualOptima is the transcendent healthcare analytics system for performance enhancement to achieve optimal patient outcomes. The analytics system measures performance against evidence-based optimal clinical processes of care. The clinical data repository of QualOptima, the Qualytx integrated aggregate clinical database, is planned to become the international common data platform for health and healthcare. Qualytx will then be capable of transforming personal health and healthcare through knowledge solutions founded on Quture's proprietary science of knowing what to measure, where that data resides in disparate databases, using the InterSystems technology to electronically abstract that data, and converting data to knowledge and actionable insight with its revolutionary and proprietary analytics system. As America transitions to payment for value and U.S. and international pressures converge to measure performance, Quture will navigate the future of global health and healthcare quality, patient safety and value.
This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern; adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs; customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that a definitive agreement will be completed.